Digital ECG Analysis and Cardiologist Experience

Richmond Pharmacology provides their clients with FDA compliant manual over-read QT interval measurement and analysis by a team of highly trained and experienced cardiologists.

Using the FDA compliant manual over-read approach, the QT interval is measured by our cardiologists on screen using electronic callipers (MUSE CV® Interval Editor, GE Marquette Medical Systems) with sufficient magnification allowing the measurement precision equal to the storage frequency of 500 MHz, i.e. ±1 ms. Whilst the details of the analysis can be discussed and agreed with our clients at the study design stage, as a matter of routine, in each ECG the QT interval is measured in all 12 leads. The median QT interval of all measurable beats from the 12 leads is then taken as valid for that particular ECG.

The measured and verified QT intervals are corrected for heart rate using conventional population-derived formulae (e.g. Fridericia) or an individually derived formula. The QT/QTc interval data are then subjected to a statistical analysis in accordance with the current regulatory guidelines which also includes input and interpretation of the results from one of our experienced cardiological scientists.

In line with the current regulatory requirements and at least every six months, all cardiologists working for Richmond Pharmacology undertake intra- and inter-reader variability tests under blinded conditions to ensure that our measurements are accurate and reproducible. Furthermore, systematic in–process QC checks are performed by a senior cardiologist during a specific study analysis. All QC checks and any corrective actions are reconciled and fully documented.

Richmond Pharmacology’s Core ECG Laboratory team are based within St George’s Hospital Medical School, London and are made up of highly experienced cardiologist’s headed by Professor John Camm, a key opinion leader in TQT Trials.

Our experts

Professor Camm - Professor of Cardiology

Professor Camm's major speciality is cardiac arrhythmias but he is also much involved in clinical cardiac electrophysiology, cardiac pacemakers and risk stratification in post myocardial infarction, heart failure and cardiomyopathy drugs.

Read biography

Dr Jorg Taubel - MD FFPM
(CEO)

Medical practitioner and CEO of Richmond Pharmacology which he co-founded in 2001. He has worked in pharmacology for 24 years and during that time he has conducted more than 400 early phase studies in patient, paediatric and healthy volunteers.

Read biography

Experience

  • Track record of 100% success in conducting QTC studies
  • Many of our QTc studies have been published.

Set-up

  • State of the art methods and equipment
  • Tried and tested processing for ECG adjudication and data analysis

We are

  • Excellence in ECG acquisition allows meaningful ECG analysis
  • Option to include a non-pharmacological method of proving assay sensitivity

Latest news

Upcoming Event

ACCP 2020, Translating Clinical Pharmacology Research into Patient-centered Care

21 - 23 September 2020
Dr. Jorg Taubel will be presenting posters that explore the subjects of cardiac health and diabetes.
View event

Richmond Pharmacology supports ReViral with the development of Sisunatovir

September 9, 2020
ReViral has confirmed the FDA has granted Fast Track designation to Sisunatovir.
Read more

Richmond Pharmacology helps UK patients gain early access to ultra-rare disease drug Lumasiran

August 17, 2020
Richmond Pharmacology early phase drug development update.
Read more

Dr Jorg Taubel, CEO of Richmond Pharmacology, features on the PM Live website, discussing clincial trials and COVID-19

August 11, 2020
Dr Jorg Taubel discusses some of the steps taken at Richmond Pharmacology to ensure clinical trials can continue to operate at a high standard throughout the COVID-19 pandemic.
Read more